CLEARWATER, Fla.--(BUSINESS WIRE)--Bovie Medical Corporation (NYSEMKT:BVX) (the “Company”), a medical technology company and the developer of J-Plasma®, a patented surgical product marketed and sold under the Renuvion™ Cosmetic Technology brand in the cosmetic surgery market, today announced the appointment of Laura Iversen as Director of Global Operations for Advanced Energy.
“Bovie Medical is pleased to announce the appointment of Laura Iversen to this newly created leadership position, as we continue to focus on improving our manufacturing capabilities and efficiencies to accommodate the strong demand that we anticipate for our Advanced Energy products in the years to come,” said Charlie Goodwin, Chief Executive Officer of the Company. “Ms. Iversen will be responsible for all aspects pertaining to the operations and manufacturing of our Advanced Energy portfolio. With a strong background that includes over 15 years of management experience in the manufacturing industry, including significant expertise in the medical device sector specifically, we believe that she is the ideal candidate for this position and look forward to her contributions.”
Prior to joining Bovie Medical, Ms. Iversen was the Director of Manufacturing and Lean Leader for Orluck Industries, Inc., a precision manufacturer of critical components in the Aerospace, Medical and other industries, where she oversaw the Manufacturing, Engineering, and Quality Departments. Ms. Iversen’s career highlights also include four years of experience, from 2012 until 2016, as the Director of Business Systems & Operational Excellence Champion for Cretex Companies, Inc., diversified family of manufacturing companies serving the Medical, Aerospace & Defense, Infrastructure, and Industrial markets. From 2007 until 2012, Ms. Iversen was the Manager and later Director of Business Systems for Ultra Machining Company (“UMC”), a premiere manufacturer of complex, precision machined parts and assemblies for customers across the Medical, Aerospace, Commercial, Energy and Industrial markets. From 2002 until 2007, Ms. Iversen served in several roles of increasing responsibility for Gyrus ACMI, a manufacturer of surgical devices, culminating in her promotion to Director of Materials in 2005. Ms. Iversen began her career in 1992 as a Buyer and Planner for Digi International Inc. (NASDAQ: DGII), a leading global provider of business and mission-critical and Internet of Things connectivity products and services.
About Bovie Medical Corporation:
Bovie Medical Corporation is a medical technology company and the developer of J-Plasma® (marketed and sold under the Renuvion™ Cosmetic Technology brand in the cosmetic surgery market), a patented plasma-based surgical product for cutting, coagulation and ablation of soft tissue. J-Plasma technology utilizes a helium ionization process to produce a stable, focused beam of plasma that provides surgeons with greater precision, and minimal invasiveness. The Company also leverages its expertise through original equipment manufacturing (OEM) agreements with other medical device manufacturers. For further information about the Company and its products, please refer to the Bovie Medical Corporation website at www.boviemedical.com.
Cautionary Statement on Forward-Looking Statements:
Certain matters discussed in this release and oral statements made from time to time by representatives of the Company may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Although the Company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions, it can give no assurance that its expectations will be achieved.
Forward-looking information is subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected. Many of these factors are beyond the Company's ability to control or predict. Important factors that may cause actual results to differ materially and that could impact the Company and the statements contained in this release can be found in the Company's filings with the Securities and Exchange Commission including the Company's Report on Form 10-K for the year ended December 31, 2017 and subsequent Form 10-Q filings. For forward-looking statements in this release, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The Company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise.